Real-World Evidence: Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive Breast Cancer

While clinical trials are designed to demonstrate efficacy and safety under controlled conditions, the highly selected trial populations in these studies often do not accurately reflect the general cancer patient population. The use of real-world data (RWD) to generate real-world evidence (RWE) that reflects the complexity of usual treatment patterns of oncology care and clinical outcomes represents a broader spectrum of patients and can help provide guidance on how to apply randomized, controlled trial (RCT) results more broadly.

The potential for RWE is particularly significant in oncology settings, as the optimal use of agents cannot be fully characterized prior to routine clinical use. RWE, when effectively deployed, can help bridge the gap by aiding in increasing external validity and generating evidence on the factors that determine treatment effects in the real world.

This CME Outfitters Snack will feature expert faculty discussing RCTs, RWD, and RWE, with a focus on the current RWE in the field of cyclin-dependent kinase (CDK) 4/6 inhibitors in metastatic breast cancer (MBC).

At the end of this CE activity, participants should be able to:
-Analyze real-world evidence in terms of study validity, study design, and data source to accurately interpret findings in an oncology setting.
-Assess evidence on real-world, clinical experience for CDK 4/6 inhibitors in MBC.